EMAS Position Statements and Clincial Guides
Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society
Life expectancy has considerably increased since 1970 [1], and now >50% of women are expected to break the 90-year barrier by 2030 [2]. Growing older rather than old means spending almost half of life after the menopause, challenging the concept of healthy ageing [3]. Iatrogenic menopause may be induced by cancer treatment or bilateral salpingo-oophorectomy for benign disease and may occur before the average age of natural menopause, which is around the age of 50 [4,5]. The sudden fall in estrogen levels with iatrogenic menopause may lead to rapid onset of vasomotor symptoms [4].The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement
Women's health is increasingly recognized as a global health priority [1]. The menopause, or the cessation of menstruation, is a stage of the life cycle which will occur in all women. The average age at menopause is 51 years. With increasing life expectancy many women will live for several decades after the menopause. However, the menopause can occur much earlier, either naturally, with no identifiable underlying cause [2], or as a consequence of disease, surgery, radiotherapy or chemotherapy. The resulting estrogen deficiency may lead to menopausal symptoms which, for some, can present considerable difficulties in their working lives, discrimination in the workplace and even unemployment [3].Global consensus recommendations on menopause in the workplace: A European Menopause and Andropause Society (EMAS) position statement
The menopause, or the cessation of menstruation, is a normal stage of life. The average age of the menopause is 51 years. However, it can occur much earlier, either naturally, with no identifiable underlying cause [1], or as a consequence of disease, surgery, radiotherapy or chemotherapy. In 2020, globally 657 million women were aged 45–59 [2] (Fig. 1). Overall, 47% of these women worldwide contributed to the labor force, but the figures varied both regionally, ranging from 22% to 63%, as well as by age: 64%, 59%, 51%, at age 45–49, 50–54, and 55–59 respectively [3].Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide
Vulvovaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM), is caused by estrogen deficiency. It is characterized by symptoms of dryness, burning, itching and dyspareunia [1]. It is well established that it has a negative impact on a woman's general and sexual quality of life as well as the quality of her personal relationships [2]. VVA is also associated with urinary tract problems, such as frequent urination, urge incontinence and recurrent urinary tract infections. GSM includes both genital and urinary symptoms [1].
